554 Results for "

AGEs

" in MedChemExpress (MCE) Product Catalog:

Products (554)

Sort by :

Categories

By Targets

Hosts:

Reactivities:

Applications:

Isotypes:

Conjugations:

Clonalities:

Modifications:

Products

305

Verteporfin

305 Publications Verification

Cat. No.: HY-B0146

CAS No.: 129497-78-5

Synonyms: CL 318952

Target:

YAP Apoptosis Autophagy Photosensitizer

Research Areas:

Cancer

Verteporfin (CL 318952) is a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as age-related macular degeneration. Verteporfin is a YAP inhibitor which disrupts YAP-TEAD interactions. Verteporfin induces cell apoptosis . Verteporfinis an autophagy inhibitor that blocks autophagy at an early stage by inhibiting autophagosome formation .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

200

MitoTEMPO hydrate

200 Cited Publications

Cat. No.: HY-125944

CAS No.: 1569257-94-8

Purity: 98.03%

Target:

Mitochondrial Metabolism PINK1/Parkin NOD-like Receptor (NLR) Autophagy Calcium Channel Apoptosis

Research Areas:

Cardiovascular Disease Neurological Disease Metabolic Disease Endocrinology

MitoTEMPO hydrate is a mitochondria-targeted antioxidant . MitoTEMPO hydrate induces mitophagy by activating the PINK1/Parkin pathway, inhibits NLRP3 inflammasome activation, restores mitochondrial membrane potential, and improves renal function and podocyte injury. MitoTEMPO hydrate regulates Ca ²⁺ homeostasis, inhibits Bnip3 overexpression, shortens action potential duration, and exerts antiarrhythmic effects. MitoTEMPO hydrate reverses premature senescence, reduces trabecular bone loss, and decreases cell apoptosis. MitoTEMPO hydrate can be used in studies of chronic kidney disease, age-related cardiac dysfunction, postmenopausal osteoporosis, and ischemic stroke .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

200

Mito-TEMPO

200 Cited Publications

Cat. No.: HY-112879

CAS No.: 1334850-99-5

Purity: 99.19%

Target:

Calcium Channel PINK1/Parkin Mitochondrial Metabolism Apoptosis Autophagy NOD-like Receptor (NLR)

Research Areas:

Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology

Mito-TEMPO is a mitochondria-targeted antioxidant. Mito-TEMPO induces mitophagy by activating the PINK1/Parkin pathway, inhibits NLRP3 inflammasome activation, restores mitochondrial membrane potential, and improves renal function and podocyte injury. Mito-TEMPO regulates Ca ²⁺ homeostasis, inhibits Bnip3 overexpression, shortens action potential duration, and exerts antiarrhythmic effects. Mito-TEMPO reverses premature senescence, reduces trabecular bone loss, and decreases cell apoptosis. Mito-TEMPO can be used in studies of chronic kidney disease, age-related cardiac dysfunction, postmenopausal osteoporosis, and ischemic stroke .

Compare